key: cord-0954111-kpxbboxj
authors: Liu, Menglu; Mei, Kaibo; Tan, Ziqi; Huang, Shan; Liu, Fuwei; Deng, Chao; Ma, Jianyong; Yu, Peng; Liu, Xiao
title: Liver Fibrosis Scores and Hospitalization, Mechanical Ventilation, Severity, and Death in Patients with COVID-19: A Systematic Review and Dose-Response Meta-Analysis
date: 2022-03-29
journal: Can J Gastroenterol Hepatol
DOI: 10.1155/2022/7235860
sha: 099ecfe929746e4dda1bfe11ea2394e70168b7e6
doc_id: 954111
cord_uid: kpxbboxj

METHODS: We identified relevant cohort studies that assessed the relationship between liver fibrosis scores (e.g., FIB-4, NAFLD fibrosis score (NFS), and aspartate aminotransferase to platelet ratio index (APRI)) and associated prognosis outcomes by searching the PubMed, EMBASE, and medRxiv databases. The potential dose-response effect was performed using a stage robust error meta-regression. RESULTS: Sixteen studies with 8,736 hospitalized patients with COVID-19 were included. One-point score in FIB-4 increase was significantly associated with increased mechanical ventilation (RR: 2.23, 95% CI: 1.37–3.65, P=0.001), severe COVID-19 (RR: 1.82, 95% CI: 1.53–2.16, P < 0.001), and death (RR: 1.47, 95% CI: 1.31–1.65, P < 0.001), rather than hospitalization (RR: 1.35, 95% CI: 0.72–2.56, P=0.35). Furthermore, there is a significant positive linear relationship between FIB-4 and severe COVID-19 (P(nonlinearity)=0.12) and mortality (P(nonlinearity)=0.18). Regarding other liver scores, one unit elevation in APRI increased the risk of death by 178% (RR: 2.78, 95% CI: 1.10–6.99, P=0.03). Higher NFS (≥−1.5) and Forns index were associated with increased risk of severe COVID-19 and COVID-19-associated death. CONCLUSION: Our dose-response meta-analysis suggests high liver fibrosis scores are associated with worse prognosis in patients with COVID-19. For patients with COVID-19 at admission, especially for those with coexisting chronic liver diseases, assessment of liver fibrosis scores might be useful for identifying high risk of developing severe COVID-19 cases and worse outcomes.

Chronic liver diseases occur very commonly worldwide and have become one of the major global health burdens [1] . Hepatic fibrosis is the early histological change before the development of cirrhosis which is the end sequela in many liver diseases (e.g., hepatitis B or hepatitis C virus infection, chronic alcoholism, and nonalcoholic fatty liver disease the general population or patients with established cardiovascular diseases [6, 9] .

Coronavirus disease 2019 (COVID- 19) , which is caused by SARS-CoV-2, resulted in over 5 million deaths worldwide. Accumulating evidence suggests that COVID-19 is more than a respiratory disease. Broad spectra of extrapulmonary manifestations, including heart, liver, and microvascular injuries, were also widely observed in patients with COVID-19. ese extrapulmonary manifestations served as the strongest predictors for severity and mortality due to COVID-19 [10, 11] . With the ongoing COVID-19 pandemic, preexisting chronic liver diseases are found to be one of the highest prevalent comorbidities [12] . Ji et al. reported that the NAFLD has been reported in up to 38% of patients with COVID-19, and it has been associated with a worse prognosis [13, 14] . Moreover, the liver fibrosis score that assesses the advanced fibrosis (e.g., FIB-4 and NFS) was also correlated with increased risk for mechanical ventilation (MV), intensive care, and mortality [15, 16] ; however, with inconsistent results [17] [18] [19] . Furthermore, we noted that the liver fibrosis scores and clinical outcomes in patients with COVID-19 were not comprehensively assessed. Given these circumstances, this systematic review and meta-analysis aimed to evaluate the relationship between liver fibrosis scores and adverse outcomes in patients with COVID-19, as well as potential dose-response association.

is study is a PRISMA-compliant (2021) systematic review and meta-analysis [20] . In addition, the protocol was prospectively registered with the international prospective register of systematic reviews (PROSPERO), and the registration number is CRD42021265872 ( see Supplementary  Table S1 ).

Four databases such as PubMed, Embase, medRxiv, and Cochrane Library were initially searched, up to June 5 th 2021. e search terms on liver fibrosis scores (such as FIB-4, NFS, and APRI) and clinical outcomes (hospitalization, MV, intensive care unit (ICU) admission, severe COVID-19, and mortality) in patients with COVID-19 were used with no language restriction. e full search strategy was described in detail in Supplementary  Table S2 . In addition, the reference lists of the relevant articles or reviews were further explored.

We included articles that met the following criteria: (1) studies reporting the associated clinical outcomes (hospitalization, mechanical ventilation (MV), severe COVID-19, and death) with noninvasive liver fibrosis scores in adult patients with COVID-19; (2) elucidations reporting the adjusted estimate (odds ratio (OR), risk ratio (RR), or hazard ratio (HR)) and corresponding 95% CI of the relevant outcomes;

(3) cohort studies. Case reports, case-serial reports, comments, and reviews were excluded from the analysis. Furthermore, case-control studies and articles reporting unadjusted results were excluded to reduce bias. Two authors (XL and PY) independently conducted the above process, and inconsistencies were rectified by discussing with the third author.

Assessment. Data were extracted based on the prespecified inclusion criteria. e following information was abstracted: study characteristics (first author's name, publication year, country in which the study was conducted, and study design), patient characteristics (sample size, age, and sex), exposures (number of fibrosis cases), and outcomes (number of events, adjusted ORs/RRs/HRs and the corresponding 95% CI, and adjustments).

e Newcastle-Ottawa quality scale (NOS) was applied to assess the quality of nonrandomized studies. Studies with a NOS of ≥6 stars were considered as moderate to highquality articles [21] .

We used the random effect model to make our results more reliable, considering the potential heterogeneity. e study-specific RRs and 95% CIs for onepoint increment in liver fibrosis scores were calculated using the Greenland and Longnecker method [22] . e nonlinear dose-response relationship was fitted following the method described by Xu and Doi [23] . It requires at least two levels of quantitative exposure categories and the corresponding RRs and variance estimates [23] . If the liver fibrosis score was not directly reported or reported in ranges, we estimated the midpoint of each category by averaging the lower and upper boundaries of that category [24, 25] . If the highest or lowest class was open-ended, we assumed that the open-ended interval length was the same as the adjacent interval [26] . In this study, the OR and HR were equally treated as RR according to our previous articles [22] . ICU admission was also defined as severe COVID-19 as we previously described [27] . We evaluated the degree of heterogeneity among the studies included in the analysis using the I 2 test (25%, 50%, and 75% represent low, moderate, and high heterogeneity, respectively) [27, 28] . Sensitivity analyses were performed by omitting each study in turn. Stata software (version 16.0) and RevMan software (version 5.3, Cochrane Collaboration, Nordic Cochrane Center Copenhagen, Denmark) were used for statistical analysis. All statistical tests were doublesided, and P < 0.05 considered statistically significant. Figure 1 , 1737 studies were initially retrieved by searching the PubMed, Cochrane Library, medRxiv, and Embase databases. We excluded 421 duplicated records and 285 articles, which were not relevant to the study objective after reviewing the title and abstract. Sixteen articles [15, 16, 18, 19, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] were finally included after excluding 15 reports for the following reasons: (1) reports that did not report the relevant clinical outcomes or target population (N � 8), (2) elucidations that were case reports or consisted only of comments (N � 5), and (3) studies that reported results with an unadjusted estimate effect (N � 2). e detailed exclusion criteria for each study are described in Supplementary Table S3 .

e basic characteristics of the studies included are described in Table 1 . Overall, sixteen cohorts (fifteen retrospective [15] [16] [17] [18] [19] [29] [30] [31] [32] [33] [34] [36] [37] [38] [39] [40] and one prospective [35] ) involving 8,736 hospitalized patients with COVID-19 were included. All COVID-19 cases were diagnosed by real-time PCR. e mean age ranged from 47 to 72 years, and five reports were from the US. Five studies were from Europe, and six publications were from Asia. Ten [15, 16, 18, 29, [31] [32] [33] [34] 36, 38] articles reported FIB-4, three [30, 35, 40] reported aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio, one [39] reported NFS, one reported FIB-4 and NFS [37] , and one [19] assessed FIB-4 and Forns index score. All studies were found to be acceptable (N ≥ 6) elucidations assessed by the NOS (see Supplementary Table S4 ).

Outcomes in irteen [15-29, 31-34, 36-38 ] studies reported FIB-4 and associated clinical outcomes in patients with COVID-19. Two studies reported hospitalization, two elucidations reported MV, five studies reported severity, and six studies reported death ( Table 1 ). As shown in Figure 2 , one-point score increase in FIB-4 was significantly associated with the increased MV (RR: 2.23, 95% CI: 1.37-3.65, P � 0.001, I2 � 0%), severe COVID-19 (RR: 1.82, 95% CI: 1.53-2.16, P < 0.001, I2 � 0%), and death (RR: 1.47, 95% CI: 1.31-1.65, P < 0.001, I2 � 0%), rather than hospitalization (RR: 1.35, 95% CI: 0.72-2.56, P � 0.35, I2 � 0%). All the pooled results showed no evidence of heterogeneity. In addition, there was a linear association between FIB-4 and severe COVID-19 (P nonlinearity � 0.12) and death (P nonlinearity � 0.18) in patients with COVID-19 ( Figure 3 ).

ree studies reported an association between the AST/ALT ratio and death. e results showed that one unit elevation in AST/ALT ratio Canadian Journal of Gastroenterology and Hepatology 5 [37] reported that higher NFS (≥−1.5) increased the risk of developing severe COVID-19 by ten-fold after adjustments. Romero-Cristobal et al. [19] showed that a one-point increment in the Forns index increased the risk of death by 41% through a multivariate analysis.

Publication bias was not evaluated because of the limited number of studies according to the guideline (N < 10) [41] . e results were stable in the sensitive analysis by omitting one study at a time (Supplementary Figure S1 ).

To our best of knowledge, this is the first comprehensive meta-analysis that assessed the live fibrosis scores and clinical outcomes in patients with COVID-19, as well as the potential dose-response relationship. Based on current evidence, we showed that all available liver fibrosis scores, including FIB-4, Forn, NFS, and AST/ALT ratio, were associated with a worse prognosis in patients with COVID-19. Moreover, there was a positive linear relationship between the FIB-4 and severe COVID-19 and death.

Several noninvasive methods were developed using serum biomarkers (e.g., FIB-4, NFS, and APRI) to assess liver fibrosis [42] . Previous studies have shown that liver fibrosis is associated with increased mortality due to cardiovascular risk and all-cause mortality in patients with liver diseases or the general population [9, 43, 44] . In the present study, we found a positive association between liver fibrosis scores and adverse outcomes. ese results were consistent with the recent findings, which reported worse outcomes in COVID-19 patients with preexisting chronic liver diseases [45] . For example, FIB-4 was found to be an independent factor of mortality among hospitalized COVID-19 patients with imaging-or liver biopsyproven NAFLD [46] . Sachdeva et al. found that the NFLAD was a strong predictor for mortality in patients infected with SARS-CoV-2 [13, 45] . It should be noted that the prevalence of chronic liver diseases is low (3%) in previous pooled analysis [47] , which might be vastly underestimated. e rate of liver fibrosis assessed by the liver fibrosis score is much larger than the prevalence of chronic liver diseases. For example, the cohort in the study by Sterling et al. had a high frequency of increased FIB-4 (52% had a FIB-4 level of >2.67 and 42% had a FIB-4 level of >3.25); however, there was low prevalence of known underlying liver disease (6%). In general, FIB-4 or NFS scores have shown higher negative predictive value but lower positive predictive value. at is to say, they have better accuracy in excluding rather than in identifying advanced fibrosis. e presence of advanced fibrosis might be underestimated in COVID-19 patients. erefore, these liver fibrosis scores provide valuable information for patients with liver comorbidities with COVID-19 and can be an effective prognostic marker for predicting their prognosis.

Moreover, the current evidence shows that FIB-4 and NFS did not perform accurately in some population, such as younger patients (< 35 years) and lean and morbidly obese adults [48, 49] . e average mean age and BMI of included studies ranged from 47 to 72 years and 24.1 to 30.8 kg/m 2 , respectively. Moreover, subgroup analyses stratified by mean age and mean BMI cannot be performed due to data restriction. e prognosis role of liver fibrosis in the COVID-19 population should be further studied.

It should be pointed out that these noninvasive assessments should be interpreted with caution due to more complexities during COVID-19 progression. Apart from the underestimated prevalence of NAFLD, we speculated that the elevation of these indicators was likely due to multiple factors but was linked to the COVID-19 disease pathogenesis and severity [10, 11] . Muscular injuries and hepatocellular and portal system alterations due to SARS-CoV-2 infection and systemic inflammation play a role in these outcomes. e components of these scores, such as AST, ALT, and platelet levels, largely fluctuated with the natural history of COVID-19 [32] . Several studies showed that the AST and ALT were significantly increased due to the high incidence of liver injury in COVID-19 patients [50] . e FIB-4 level was correlated to SARS-CoV-2 plasma RNA level as well as monocyte-associated cytokine levels [32] . erefore, we should figure out whether the prevalence of liver fibrosis in COVID-19 can be solely attributed to chronic liver diseases and whether the associated incidence of liver injury can be caused by ere might be several potential mechanisms in the pathogenesis of chronic liver disease. Inflammation has a vital role in the pathogenesis of liver fibrosis [51] . Chronic inflammation is firmly established, and advanced liver disease is characterized by low-grade systemic inflammation caused by activated immune cells [51] . ese activated cells serve as a vital source of cytokines and chemokines (e.g., interleukin-6, interleukin-18, and interleukin-17). Furthermore, Li et al. showed a positive association between FIB-4 scores and interleukin-6 levels in patients with COVID-19 [32] . Some researchers proposed that this elevated interleukin-6, which is partly secreted by activated macrophages induced during liver fibrosis, might induce inflammatory response proteins in the hepatocytes (such as CRP (C-reactive protein), ferritin, complement, and clotting factors) [31] . Meanwhile, as it is known, an excessive inflammatory response is a relative phenomenon of severe COVID-19 cases. erefore, it is reasonable to speculate that liver fibrosis may increase the risk of exacerbated inflammatory responses.

Overall, our results showed that the liver fibrosis scores were associated with the worst prognosis and might be a simple marker for predicting the severity and mortality in patients with COVID-19. All the components of these liver fibrosis scores (e.g., age, AST, and ALT) were accessible, and determining the levels of these markers was inexpensive. However, importantly, we did not assess the correlation between the presence of fibrosis and the most accurate assessment test, liver biopsy. Admittedly, liver biopsy is the current gold standard test for assessing liver fibrosis. However, it is unfeasible, probably unethical, and difficult to perform routinely. Furthermore, liver fibrosis scores were the results of multiple and complex factors involved in the natural progression of SARS-CoV-2 infection and should not be merely considered as an assessment for liver fibrosis.

is is the first meta-analysis to comprehensively assess the liver fibrosis scores and associated clinical outcomes in patients with COVID-19 and elucidate the positive linear association between the FIB-4 and adverse outcomes. Our study inevitably has several limitations. Firstly, this is an analysis of observational research, which cannot prove causation. Secondly, the number of studies included was relatively limited, and prospective, longitudinal, larger studies were needed to validate the predictive ability of liver fibrosis scores.

irdly, as the components of liver fibrosis scores varied during trajectories of COVID-19, the inconsistent timepoint of assessment included in evaluations, the studies inevitably increased the instability of predicting adverse outcomes in patients with the COVID-19. Fourthly, the specificity of FIB-4 for determining advanced fibrosis in patients ≥65 years decreases significantly and may overestimate the liver fibrosis level [49] . However, we cannot perform a subgroup stratified analysis by age. Further studies should focus on determining if there is an age difference.

Overall, our results suggested that liver fibrosis scores, such as FIB-4, NFS, AST/ALT ratio, and Forns index were significantly associated with the increased risk of MV, severe COVID-19, and mortality. For patients with COVID-19 at admission, especially for those with coexisting chronic liver diseases, assessment of liver fibrosis scores might be useful for identifying high risk of developing severe COVID-19 cases and worse outcomes.

Data Availability e datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Liu and Kaibo Mei are co-first authors.

e authors declare that there are no conflicts of interest.

X-L and P-Y were responsible for the entire project and revised the draft. S-H, K.B-M, and C-D performed the data extraction, statistical analysis, drafted the first version of the manuscript, and interpreted the data. All authors participated in the interpretation of the results and prepared the final version of the manuscript. Menglu Liu and Kaibo Mei contributed equally.

Burden of liver diseases in the world

High prevalence of liver fibrosis among European adults with unknown liver disease: a population-based study

Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease

Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review

Simple scores of fibrosis and mortality in patients with NAFLD: a systematic review with meta-analysis

Liver fibrosis scores predict liver disease mortality in the United States population

Fibrosis-4 index, a noninvasive fibrosis marker, predicts survival outcomes after hepatectomy for colorectal cancer liver metastases

Profile and value of FIB-4 in patients with dual chronic hepatitis C and B

Liver fibrosis marker is an independent predictor of cardiovascular morbidity and mortality in the general population

Extrapulmonary manifestations of COVID-19: radiologic and clinical overview

Postmortem findings in Italian patients with COVID-19: a descriptive full autopsy study of cases with and without comorbidities

Prevalence of comorbidities among individuals with COVID-19: a rapid review of current literature

Non-alcoholic fatty liver diseases in patients with COVID-19: a retrospective study

Liver injury is associated with severe coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of retrospective studies

e impact of increased Fib-4 score in patients with type II diabetes mellitus on Covid-19 disease prognosis

Impact of Fibrosis-4 index prior to COVID-19 on outcomes in patients at risk of non-alcoholic fatty liver disease

Association of liver steatosis and Fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19)

In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19

Possible unrecognised liver injury is associated with mortality in critically ill COVID-19 patients

PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: a rapid systematic review and meta-analysis

Resting heart rate and the risk of atrial fibrillation

e robust error meta-regression method for dose-response meta-analysis

e obesity paradox for outcomes in atrial fibrillation: evidence from an exposureeffect analysis of prospective studies

e relationship between vitamin D and risk of atrial fibrillation: a dose-response analysis of observational studies

Green tea consumption and risk for esophageal cancer: a systematic review and dose-response meta-analysis

Prevalence and impact of cardiac injury on COVID -19: a systematic review and meta-analysis

Handbook for Systematic Reviews of Interventions

e Fibrosis-4 index is associated with Intensive Care Unit (ICU) admission in middle-aged patients with COVID-19

e liver in COVID-19: prevalence, patterns, predictors, and impact on outcomes of liver test abnormalities

Elevation of liver fibrosis index FIB-4 is associated with poor clinical outcomes in patients with COVID-19

Liver fibrosis index Fib-4 is associated with mortality in COVID-19

Fibrosis-4 index as a predictor for mortality in hospitalised patients with COVID-19: a retrospective multicentre cohort study

Covid-19 testing, hospital admission, and intensive care among 2,026,227 United States veterans aged 54-75 years

Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; the APCOLIS Study (APASL COVID-19 liver injury spectrum study)

e Fibrosis-4 index is associated with need for mechanical ventilation and 30-day mortality in patients admitted with coronavirus disease 2019

Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores

Early elevation of Fib-4 liver fibrosis score is associated with adverse outcomes among patients with COVID-19

Risk of severe illness of COVID-19 patients with NAFLD and increased NAFLD fibrosis scores

Influence factors of death risk among COVID-19 patients in Wuhan, China: a hospitalbased case-cohort study

Cochrane Handbook for Systematic Reviews of InterventionsJohn Wiley & Sons

Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers

e enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease

Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes

NAFLD and COVID-19: a pooled analysis

Independent predictors of mortality among patients with NAFLD hospitalized with COVID-19 infection

Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis

Accuracy of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease according to body mass index: failure in the prediction of advanced fibrosis in lean and morbidly obese individuals

Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis

An updated metaanalysis of AST and ALT levels and the mortality of COVID-19 patients

Molecular and cellular mechanisms of liver fibrosis and its regression

Acknowledgments e authors acknowledge all people who fought against COVID-19. is work was supported by a grant from the Natural Science Foundation in Jiangxi Province (Nos. 20192ACBL21037 and 202004BCJL23049) and the National National Natural Science Foundation of China (Nos. 81760050, 82100869, and 21866019).

Figure S1: sensitive analysis between liver fibrosis scores and clinical outcomes in patients with COVID-19 by omitting one study at a time. A: severe COVID-19; B: death. Supplementary Table S1 : PRISMA 2020.